Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Launched by UNIVERSITY OF LATVIA · Jul 21, 2017
Trial Information
Current as of November 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study, called Volatolome, is watching whether signals from volatile organic compounds (VOCs) in breath and in the headspace around tissues (like skin or surgical material) can help diagnose or monitor diseases of the digestive system and related infections. Researchers will use a new, affordable nano-sensor “electronic nose” and other lab analyses to see if these VOC patterns can accurately identify conditions such as tuberculosis, various stomach and colorectal changes, gastric and pancreatic cancers, chronic liver or pancreatic diseases, and inflammatory bowel disease. The main goal is to see how well breath and headspace VOC tests work (in terms of sensitivity, specificity, and overall accuracy) for detecting the targeted diseases.
Who can join and what to expect: the study plans to enroll up to 3,000 adults, including people who have one of the targeted diseases or high‑/low‑risk digestive lesions, as well as healthy volunteers from the general population. Key inclusion is a signed informed consent and having a targeted disease/lesion or being healthy for comparison. Exclusion is only that consent isn’t signed or there’s another active cancer at the time of entry. This is an observational study, not a treatment trial, so participants may provide breath samples and blood or stool samples, and some may undergo procedures like upper endoscopy or colonoscopy with biopsies as part of standard care. The researchers will follow VOC patterns over time, including after treatment when relevant, to see if changes in VOCs relate to illness or recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent signed
- • Individual with targeted disease/lesion (tuberculosis, gastric cancer, gastric dysplasia, high/ normal/ low risk gastric lesions, colorectal cancer, high-risk colorectal lesions, low-risk colorectal adenoma, pancreatic cancer, chronic pancreatitis, liver cancer, chronic liver disease, other infectious diseases, oncological diseases of other location)
- Exclusion Criteria:
- • Informed Consent not signed
- • Other active cancer at the time of inclusion for particular study group
About University Of Latvia
The University of Latvia is a leading academic institution dedicated to advancing knowledge and research in various fields, including medicine and health sciences. As a clinical trial sponsor, the University leverages its extensive expertise and resources to facilitate innovative research initiatives aimed at improving patient outcomes and contributing to the scientific community. The institution prioritizes ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost integrity and a commitment to participant safety. Through collaboration with healthcare professionals and researchers, the University of Latvia fosters an environment that encourages groundbreaking discoveries and enhances the quality of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riga, Latvia
Patients applied
Trial Officials
Mārcis Leja, PhD, MD
Study Director
University of Latvia
Lelde Lauka, MD
Principal Investigator
University of Latvia
Andra Cīrule, MD
Principal Investigator
Riga East University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials